Jefferies analyst Roger Song raised the firm’s price target on Allogene Therapeutics (ALLO) to $10 from $6 and keeps a Buy rating on the shares following interim data from the ALPHA3 trial evaluating cema-cel in first-line consolidation for large B-cell lymphoma that the firm says “clearly exceeded expectations.” The firm see significant upside potential from here, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALLO:
- Unusually active option classes on open April 15th
- Allogene Therapeutics 87.5M share Spot Secondary priced at $2.00
- Allogene Therapeutics price target raised to $3.85 from $1.60 at Bernstein
- Allogene Therapeutics price target raised to $9 from $7 at Baird
- Allogene Therapeutics price target raised to $12 from $8 at H.C. Wainwright